Sudeep Pharma Limited has announced a schedule for meetings with analysts and institutional investors in Gujarat. The company will host participants for plant visits on September 23 and 24, 2026.

The interactions are scheduled to begin at 11:00 am on both days. Discussions during these visits will be strictly based on publicly available information. The company stated that no unpublished price-sensitive information (UPSI) is intended to be discussed during the interactions.

Regulatory Disclosure

This intimation was submitted pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Dimple Mehta, the Company Secretary and Compliance Officer, on September 16, 2026.

Event Details

The company noted that changes to the schedule may occur due to exigencies on the part of the participants or the company. Sudeep Pharma’s registered office is located in Nandesari, Vadodara, while its corporate office is situated in Sevasi, Vadodara.

Sudeep Pharma Limited reported a 30% year-on-year increase in consolidated net profit to ₹40.6 crore for the quarter ended June 30, 2026 (Q1FY27), driven by a 27% surge in revenue from operations to ₹158.3 crore. The company released the full transcript of its earnings call held on August 5, 2026, providing deeper insights into the performance drivers. Management highlighted that growth was predominantly volume-led in the Pharma, Food, and Nutrition (PFN) segment, while the Specialty Ingredients business faced temporary headwinds due to LPG supply constraints. Despite geopolitical uncertainties and elevated logistics costs, the company maintained an EBITDA margin of 34.69%, underscoring resilient operational efficiency.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 4, 2026, in compliance with Regulation 30(6) of the SEBI Listing Regulations, 2015. Statutory auditor B S R and Co conducted a limited review pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The review covered financial statements prepared under Indian Accounting Standard 34 (Ind AS 34). Milin Mehta was appointed as an Independent Director during the quarter, bringing expertise in strategy and corporate governance to strengthen the Board.

Financial Performance

Consolidated total income reached ₹163.7 crore, up from ₹130.1 crore in Q1FY26. Other income stood at ₹5.4 crore. Total expenses were ₹109.4 crore, comprising cost of materials consumed at ₹56.6 crore and employee benefits expense at ₹14.3 crore. Profit before tax rose to ₹54.3 crore from ₹44.1 crore in the prior year period. The following table summarises the key consolidated financial metrics for the quarter:

Standalone net profit increased to ₹33.8 crore from ₹25.2 crore. Standalone revenue from operations grew to ₹105.7 crore. Earnings per share (basic) were ₹3.59 on a consolidated basis and ₹3.00 on a standalone basis.

Segment Analysis and Strategic Initiatives

The pharmaceutical, food, and nutrition segment generated external revenues of ₹108.4 crore, up significantly from ₹83.0 crore in Q1FY26, with a segment result before other income, finance costs, and tax of ₹41.9 crore. Management clarified that this 31% growth was predominantly volume-driven, with only about 3% attributed to currency changes. Price increases for phosphoric acid, which rose approximately 50% due to sulfur price hikes, are expected to be passed through to customers largely in Q2FY27.

The speciality ingredients segment reported external revenues of ₹49.9 crore, up from ₹41.9 crore, yielding a segment result of ₹13.1 crore. However, margins dipped to 26% due to temporary operational constraints from an LPG supply shortage in April and May, which reduced utilization to below 50%. Excluding the European subsidiary NSS, which faced challenges due to high energy costs and subdued demand, the core specialty business maintained mid-30s margins. NSS integration is progressing, with five new customer approvals secured since June.

Capacity Expansion and Battery Materials

The ₹300 crore Battery Materials Plant in Dahej, Gujarat, aims to produce Battery Grade Iron Phosphate for EV and Energy Storage applications on an 80,980 sq. mt. land area. Financing will be through internal accruals and debt. Sudeep Pharma positions itself as a premier non-Chinese supplier for battery-grade iron phosphate PCAM, leveraging FEOC-compliant supply chains aligned with US IRA and EU Critical Raw Materials Act regulations.

The following table outlines the key parameters of the battery materials expansion:

Total capacity visibility is projected to rise from 65,000 MT in FY25 to 1,48,700 MT in FY27. This includes a greenfield addition of 51,200 MT in pharma, food, and nutrition, and 25,000 MT in battery materials. Existing pharma iron phosphate capacity has been enhanced to produce 5,000 MT of battery-grade material.

Management Guidance and Outlook

During the earnings call, management shared detailed guidance across business segments. The new greenfield facility for Pharma, Food, and Nutrition (PFN) is expected to be commissioned in Q3, with supplies starting from the facility in Q3. SAM Phase 1 commissioning is now targeted by April 2027, with major long-lead equipment deliveries expected by October. SAM is also evaluating an expansion from 100 kTPA to 200 kTPA, with a target to reach 200 kTPA between FY30 and FY31, contingent on concluding binding off-take agreements later this year.

The following table summarises key guidance parameters shared by management:

Management expects Q1FY27's strong momentum to continue into Q2, with a historically stronger second half, positioning the company for a year of strong growth. The specialty ingredients business is expected to return to its historical growth trajectory starting in Q2, following temporary operational constraints in Q1. NSS is expected to recover more gradually, with growth and profitability improving as European market conditions normalize, targeting margins similar to the core specialty ingredient business by FY28.

What the Numbers Show

The divergence between revenue growth (27%) and expense growth (27.2%) indicates stable operating leverage, while the slight dip in EBITDA margin from 35.12% to 34.69% reflects minor pressure from higher material or logistics costs. The pharmaceutical, food, and nutrition segment remains the primary profit driver, contributing approximately 82% of the total segment result before tax. The successful integration of NSS and the strategic pivot into battery materials highlight a dual-growth strategy: consolidating market leadership in excipients while capturing high-value opportunities in the energy storage sector.